Skip to main content
Theradiag logo

Theradiag — Investor Relations & Filings

Ticker · ALTER ISIN · FR00140069U4 LEI · 969500CDG241WHIFL611 PA Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2022-09-23 M&A Activity
Country FR France
Listing PA ALTER

About Theradiag

https://www.theradiag.com/en/home-2/

Theradiag is a company that develops, manufactures, and markets in-vitro diagnostic (IVD) solutions, with a primary focus on theranostics. The company specializes in creating tools for monitoring biotherapies, which are treatments using substances derived from living organisms. Its core product line, Lisa-Tracker, is a range of kits designed to help clinicians measure the efficacy of biotherapies, particularly for patients with autoimmune diseases. This allows for the personalization of treatment and improved patient outcomes. In addition to its focus on biotherapy monitoring, Theradiag also maintains its activities in developing and distributing diagnostic tests for autoimmunity and oncogenetics. The company leverages its extensive experience to provide innovative diagnostic tools for clinicians and patients.

Recent filings

Filing Released Lang Actions
News releases during takeover bids / Takeover bids Other news releases
M&A Activity Classification · 1% confidence The document is a press release announcing that Biosynex has filed a voluntary takeover bid (tender offer) for Theradiag shares with the AMF (French financial markets authority). This clearly falls under the category of Merger & Acquisition (M&A) activity or a takeover proposal. The definition for M&A Activity (Code: TAR) covers 'Announcements and documents related to merger proposals or takeover bids.' Although the document mentions the filing of the offer, it is the substance of the takeover bid itself, not just an announcement of a future report release, making TAR the most specific fit over the general RPA or RNS.
2022-09-23 English
Communiqués publiés en période d'offre publique d'acquisition / OPA Autres communiqués
M&A Activity Classification · 1% confidence The document is a press release announcing that Biosynex has filed a voluntary cash tender offer (Offre publique d'achat volontaire en numéraire) to acquire Theradiag shares. This action directly relates to a merger or takeover proposal. According to the definitions, the code for M&A Activity is TAR. The document details the offer price, premium, and board reaction, confirming it is a primary announcement regarding a takeover bid, not a general regulatory filing (RNS) or a report itself.
2022-09-23 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is an announcement of half-year financial results for Theradiag for the period ending June 30, 2022. It includes key financial highlights, tables comparing H1 2022 to H1 2021, management commentary, and operational updates. While it contains financial data, it is structured as a press release announcing the results rather than the full, formal interim financial report itself. According to the filing definitions, this is an Earnings Release (ER). H2 2022
2022-09-19 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is a press release from Theradiag announcing its financial results for the first half of 2022 (S1 2022). It includes key financial highlights, tables comparing S1 2022 to S1 2021, management commentary, and an outlook for the future. While it contains financial data, it is structured as an initial announcement of results (Earnings Release) rather than a full, comprehensive interim report. It follows the standard format for an earnings release, providing highlights and key performance indicators to the market. H2 2022
2022-09-19 French
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is titled "Theradiag reports revenue of €6.3 million for the first half of 2022, up 14.3%" and explicitly details financial performance metrics (revenue, cash position) for the six-month period ending June 30, 2022. This content structure—presenting key financial figures for a period shorter than a full year, often accompanied by management commentary—is characteristic of an Interim/Quarterly Report. Although it is a press release announcing the results, the depth of the data provided (tables with comparative figures, segment breakdowns) suggests it is more than just a brief Earnings Release (ER). It is a comprehensive summary of the half-year performance, fitting the definition of an Interim Report (IR). The document also mentions the upcoming 'H1 2022 results' release on September 19, 2022, which implies this document is the preliminary revenue announcement or the interim report itself, but given the detailed financial breakdown, IR is the most appropriate classification over ER or RPA. H1 2022
2022-07-18 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled "Theradiag annonce un chiffre d'affaires semestriel 2022 de 6,3 M€, en croissance de 14,3%" and presents detailed financial figures (revenue, cash position) for the first half of 2022 (ending June 30, 2022). This content structure—presenting key financial metrics for a period shorter than a full year—is characteristic of an Interim/Quarterly Report. Although it is an announcement of results, the text provides substantial detail, including tables and management commentary, making it more than just a brief 'Earnings Release' (ER). It is a comprehensive report for a half-year period, fitting the definition of an Interim Report (IR). The document also explicitly mentions the upcoming release of the 'Résultats du 1er semestre 2022' on September 19, 2022, confirming the nature of the current document as the preliminary or actual interim results disclosure. H1 2022
2022-07-18 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.